Prevention of duodenal ulcer relapse with ranitidine.
S Afr Med J
; 68(6): 385-6, 1985 Sep 14.
Article
en En
| MEDLINE
| ID: mdl-3898417
ABSTRACT
Forty-three patients with a recently healed duodenal ulcer were entered into a 1-year double-blind trial to evaluate the efficacy and tolerance of ranitidine (Zantac; Glaxo). There were no drop-outs. After 1 year 18 of the 22 patients receiving 150 mg ranitidine at night (82%) and 3 of the 21 receiving placebo (14%) were ulcer- and symptom-free. No drug-related side-effects were noticed. A maintenance dose of ranitidine seems to be a safe and effective means of preventing duodenal ulcer recurrence.
Buscar en Google
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Ranitidina
/
Úlcera Duodenal
Tipo de estudio:
Clinical_trials
Límite:
Adult
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
S Afr Med J
Año:
1985
Tipo del documento:
Article